Qinling Granules

Qinling Granules (秦苓颗粒) is a Traditional Chinese Medicine (TCM) candidate developed by Beijing New Weipao Pharmaceutical Technology Co., Ltd. for the treatment of hyperuricemia. The formulation is specifically designed to address the 'Damp-Heat Internal Accumulation' (湿热内蕴) syndrome, a common diagnostic pattern in TCM for patients with metabolic disorders and elevated serum uric acid. As a granule-based therapy, it is administered orally and is currently undergoing clinical evaluation in China (e.g., trial CTR20250607) to assess its efficacy and safety. The drug represents a botanical approach to managing hyperuricemia, likely working through the synergistic effects of its herbal components to regulate uric acid metabolism and excretion.

Other names

秦苓颗粒